Ferroptosis inducers: A new frontier in cancer therapy
Bioorganic Chemistry · 2024
DOI: 10.1016/j.bioorg.2024.107331 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Wenjing Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 137 Literaturangaben.
Abstract (Originalsprache)
Ferroptosis represents a non-apoptotic form of programmed cell death characterized by iron-dependent lipid peroxidation. This cell death modality not only facilitates the direct elimination of cancer cells, but also enhances their susceptibility to other pharmacological anti-cancer agents. The burgeoning interest in ferroptosis has been driven by a growing body of evidence that underscores the efficiency and minimal toxicity of ferroptosis inducers. Traditional inducers, such as erastin and RSL3 have shown substantial promise in clinical applications due to their potent therapeutic effects. Their significant potential of these inducers has spurred the development of a variety of small molecule ferroptosis inducers. These novel inducers boast an enhanced structural variety, improved metabolic stability, the capability to initiate ferroptosis without triggering apoptosis, making them well-suited for in vivo use. Despite these advancements, challenges still remain, particularly concerning the drug delivery, tumor specificity, and circulation duration of these small molecules in vivo. Addressing these challenges, contemporary research has pivoted towards innovative delivery systems tailored for ferroptosis inducers to facilitate precise, targeted, and synegestic therapeutic delivery. This review scrutinizes the latest progress in small molecule ferroptosis inducers and nano drug delivery systems geared towards ferroptosis sensitization. Furthermore, it delineated the prospective therapeutic advantages and the existing hurdles in the development of ferroptosis inducers for malignant tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China; Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, Hangzhou 310058, Chin…
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Ed…
Zitieren
APA
Ma, W., Hu, N., Xu, W., Zhao, L., Tian, C., & Kamei, K. I. (2024). Ferroptosis inducers: A new frontier in cancer therapy. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107331
Vancouver
Ma W, Hu N, Xu W, Zhao L, Tian C, Kamei KI. Ferroptosis inducers: A new frontier in cancer therapy. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107331
BibTeX
@article{Ma2024,
author = {Ma, Wenjing and Hu, Naiyuan and Xu, Wenqian and Zhao, Linxi and Tian, Chutong and Kamei, Ken-Ichiro},
title = {Ferroptosis inducers: A new frontier in cancer therapy},
journal = {Bioorganic Chemistry},
year = {2024},
doi = {10.1016/j.bioorg.2024.107331}
}
EUVIMED